LEI-515, a peripherally restricted MAGL inhibitor, reduced liver injury and neuropathic pain in mice through CB2 receptors without causing brain-based side effects or dependence.
Drug development scientists, pain researchers, and endocannabinoid system pharmacologists.
No CNS side effectsor dependence with LEI-515, unlike global MAGL inhibitors that caused cannabinoid-like brain effects
What the researchers found
LEI-515 increased 2-AG levels in peripheral organs but not the brain, attenuated liver necrosis and chemotherapy-induced neuropathic pain, and did not produce CB1-mediated side effects or physical dependence.
Why it matters
Previous MAGL inhibitors caused brain-related side effects similar to cannabis. LEI-515 demonstrates that peripheral-only endocannabinoid enhancement can provide therapeutic benefits without these problems.
The numbers in context
LEI-515 increased peripheral 2-AG but not brain levels. Antinociceptive effects blocked by CB2 but not CB1 antagonists. Rimonabant precipitated dependence with JZL184 and WIN55,212-2 but not LEI-515.
How the study worked
Drug discovery study combining high-throughput screening, medicinal chemistry, in vivo pharmacology (liver injury and neuropathic pain models), and dependence testing in mice.
Who was studied
Mice in CCl4-induced liver injury and chemotherapy-induced neuropathic pain models.
What this study cannot tell us
Preclinical mouse data may not translate to humans. Long-term safety of peripheral MAGL inhibition unknown. Single pain model tested. Liver injury model is acute, not chronic.
How to read the evidence
Comprehensive preclinical drug discovery study; promising but requires human clinical development.
When this study was published
Recent drug discovery report.
The bigger picture
LEI-515 represents a new therapeutic strategy — boosting the body natural endocannabinoids only outside the brain — that could provide anti-inflammatory and pain-relieving benefits without cannabis-like side effects or addiction risk.
Replication
First peripherally restricted MAGL inhibitor; clinical development pathway needed.
Funding
Not specified in abstract
Conflicts of interest
Not specified in abstract
Questions still open
- Will peripheral MAGL inhibition be sufficient for chronic pain conditions in humans?
- Could LEI-515 be combined with other pain medications for enhanced efficacy?
Read the original research
A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.
Nature communications, 14(1), 8039
Citation
Jiang, Ming; Huizenga, Mirjam C W; Wirt, Jonah L; Paloczi, Janos; Amedi, Avand; van den Berg, Richard J B H N; Benz, Joerg; Collin, Ludovic; Deng, Hui; Di, Xinyu; Driever, Wouter F; Florea, Bogdan I; Grether, Uwe; Janssen, Antonius P A; Hankemeier, Thomas; Heitman, Laura H; Lam, Tsang-Wai; Mohr, Florian; Pavlovic, Anto; Ruf, Iris; van den Hurk, Helma; Stevens, Anna F; van der Vliet, Daan; van der Wel, Tom; Wittwer, Matthias B; van Boeckel, Constant A A; Pacher, Pal; Hohmann, Andrea G; van der Stelt, Mario. (2023). A monoacylglycerol lipase inhibitor showing therapeutic efficacy in mice without central side effects or dependence.. Nature communications, 14(1), 8039. https://doi.org/10.1038/s41467-023-43606-3